2[1]Takeda S,Ishthara K, Wakui Y, et al. Bioavailability study ofglycyrrhetic acid after oral administration of glycyrrhizin in rats;relevance to the intestinal bacterial hydrolysis[J].J PharmPharmacol,1996, 48(9):902.
3[2]Van Rossum TG, Vulto AG, De Man RA, et al. Review article:glycyrrhizinas a potential treatment for chron-ic hepatitis C[J].Aliment Pharmacol Ther, 1998, 12(2):199.
4[3]Van Rossum TG, Vulto AG, Hop WC, et al.Intraveno-us glycyrrhizin for the treatment of chronic hepatitis C:a double－blind, randomized, placebo controlled pha-se I/II trial[J]. J Gastroenterol Hepatol,1999, 14(11):1 093.
5[4]Yamamura Y, Kotaki H, Tanaka N, et al. The pharmaco-kinetics of glycyrrhizin and its restorative effect on he-patic function in patients with chronic hepatitis and in chronicallycarbon-tetrachloride-intoxicated rats[J].Biopharm Drug Dispos, 1997, 18(8):717.
6[5]Yamamura Y, Santa T, Kotaki H, et al. Administrationroute dependency of absorption of glycyrrhizin in rat-
8[7]Okamoto T, Tanaka N, Vulto AG, et al. The protectiveeffect of glycyrrhizin on anti-fas antibody-inducedhepatitis in mice[J]. Eur J Pharmacol, 2000, 387(2):229.
9[8]Okamoto T, Kanda T, Vulto AG, et al. Glycyrrhizin protects mice fromconcanavalin A-induced hepatitiswithout affecting cytokine expression[J]. Int J Mol M-ecl, 1999, 4(2):149.
10[9]Tsabota A. Corrbinecl ursodeoxycholic acid and glycyrrhizin therapy forchronic hepatitis C virus infection:a randomized controlled trial in 170patients[J].Eur J Gastroenterd Hepatol, 1999, 11(10):1 077.
